Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 259-393-4 | CAS number: 54914-37-3
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
1,3,3 -Trimethyl-N-(2 -methylpropylidene)-5 -[(2 -methylpropylidene) amino]cyclohexane-methylamine is of oral and dermal acute toxicity with an oral LD50 (rat) of 4150 mg/kg bw (Hüls AG, 1985) and a dermal LD50 > 5000 mg/kg bw (Hüls AG, 1985).
Key value for chemical safety assessment
Acute toxicity: via oral route
Link to relevant study records
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1985-06-12 to 1985-07-02
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 401 (Acute Oral Toxicity)
- Version / remarks:
- (1981)
- Deviations:
- no
- GLP compliance:
- no
- Test type:
- standard acute method
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Doses:
- 3160; 3980; 5010; 6310 mg/kg bw
- No. of animals per sex per dose:
- 10
- Control animals:
- no
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- 4 150 mg/kg bw
- Based on:
- test mat.
- 95% CL:
- >= 3 517 - <= 4 897
- Mortality:
- - Number of deaths at each dose:
3160 mg/kg bw: 0 males, 2 females dead within 26 hours
3980 mg/kg bw: 1 male, 4 females dead within 24 hours
5010 mg/kg bw: 2 males, 3 females dead within 48 hours
6310 mg/kg bw: 5 males, 4 females dead within 30 hours - Clinical signs:
- other: - 30 minutes after application: Ruffled fur - later: Crouched posture, some cases of slight sedation and ataxia, staggering gait, prone position, cyanosis of the extremities, hypothermia, and narrowed or closed palpebral fissures - at 24 hours (additi
- Gross pathology:
- - animals that died during the study: Swelling of the gastric mucosa, hyperemia of the gastric and intestinal mucosa, the peritoneum and the diaphragm, and of the pancreas; formation of flecks on liver and kidneys
- terminal necropsy: Areas of whitish fur on the cardial mucosa, discoloration of the liver, conglutination and fusion of the abdominal organs with one another and with the diaphragm - Conclusions:
- The LD50 value (oral) of 1,3,3 -Trimethyl-N-(2 -methylpropylidene)-5 -[(2 -methylpropylidene)amino]cyclohexanemethylamine in female and male rats was estimated to be 4150 mg/kg bw. Therefore, under the conditions employed in this study, the acute toxicity after oral exposure in rats is low.
- Executive summary:
1,3,3 -Trimethyl-N-(2 -methylpropylidene)-5 -[(2 -methylpropylidene)amino]cyclohexanemethylamine is of low oral acute toxicity with an oral LD50(rat) of 4150 mg/kg bw (OECD 401, Hüls AG, 1985). Mortalities were observed in the oral acute toxicity study at doses > 3160 mg/kg bw. Clinical signs after oral administration like ruffled fur 30 min after application, later: crouched posture, some cases of slight sedation and ataxia, staggering gait, prone position, cyanosis of the extremities, hypothermia, and narrowed or closed palpebral fissures. At 24 h additional observations, like diarrhea and increased diuresis were made. In the two highest dose groups (i.e. 5010 and 6310 mg/kg bw respectively), difficulties with breathing, uttering sounds when touched and towards the end of the study ruffled fur in 2 animals from the high dose group were observed. Other signs disappeared approximately by day 10.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 4 150 mg/kg bw
- Quality of whole database:
- The study is reliable without restriction (Klimisch score 1)
Acute toxicity: via inhalation route
Link to relevant study records
- Endpoint:
- acute toxicity: inhalation
- Data waiving:
- other justification
- Justification for data waiving:
- other:
Reference
Endpoint conclusion
- Endpoint conclusion:
- no study available
Acute toxicity: via dermal route
Link to relevant study records
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1985-06-11 to 1985-06-25
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Version / remarks:
- (1981)
- Deviations:
- no
- GLP compliance:
- no
- Test type:
- standard acute method
- Limit test:
- yes
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- - Strain: Bor: WISW (SPF TNO)
- Source: F. Winkelmann, Borchen (Germany)
- Weight at study initiation: 5 males mean 229 g, 5 females mean 213 g - Type of coverage:
- occlusive
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- - Area covered: dorsal skin (shaved 24 hours in advance)
- Occlusion: mull patch, elastic dressing (for 24 hours) - Duration of exposure:
- - Removal of test substance: after patch removal (at 24 hours), thorough washing with warm water and swabbing with cellulose
- Post dose observation period: total duration 14 days - Doses:
- 5000 mg/kg bw (selection based on pre-test performed from 1985-05-21 to 1985-06-12)
- No. of animals per sex per dose:
- 10
- Control animals:
- no
- Details on study design:
- EXAMINATIONS:
- Body weights: before, and 1, 7, 14 days post dosing
- Clinical signs and mortality: within 6 hours after dosing, thereafter daily
- Necropsy: all animals (macroscopic) - Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 5 000 mg/kg bw
- Mortality:
- No deaths
- Clinical signs:
- other: - immediately after treatment: Vehement defense reactions, uttering sounds, both attributed to fixation of patch - at 1 hour: Ruffled fur, stretched posture, temporary uttering sounds, Straub reaction, reddish brown color of application area - after p
- Gross pathology:
- Hyperemia of the small intestinal mucosa and in one animal formation of flecks on the kidneys
- Conclusions:
- The LD50 value (dermal) of 1,3,3 -Trimethyl-N-(2 -methylpropylidene)-5 -[(2 -methylpropylidene)amino]cyclohexanemethylamine in female and male rats was estimated to be > 5000 mg/kg bw. No mortalities were observed. Therefore, under the conditions employed in this study the substance is of low dermal acute toxicity.
- Executive summary:
1,3,3 -Trimethyl-N-(2 -methylpropylidene)-5 -[(2 -methylpropylidene)amino]cyclohexanemethylamine is of low dermal acute toxicity with a dermal LD50of > 5000 mg/kg bw (OECD 402, Hüls AG, 1985).
For the dermal acute toxicity study no mortalities up to a dose of 5000 mg/kg bw were observed. Clinical signs immediately after treatment were vehement defense reactions, uttering sounds, both attributed to fixation of the patch. At 1 hour the following observations were made: ruffled fur, streched posture, temporary prone position or retarded motion, staggering gait, hypothermia and slight sedation. In the application area necrosis, incrustation of application area, wounds partly with discharge, and formation of scars were observed.
Necropsy findings were Hyperemia of the small intestinal mucosa and in one animal formation of flecks on the kidneys. The body weight was transiently inhibited.
Dermal exposure has to be avoided because of sensitizing properties.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- LD50
- Value:
- 5 000 mg/kg bw
- Quality of whole database:
- The study is reliable without restriction (Klimisch score 1)
Additional information
1,3,3 -Trimethyl-N-(2 -methylpropylidene)-5 -[(2 -methylpropylidene)amino]cyclohexanemethylamine is of low oral and dermal acute toxicity with an oral LD50(rat) of 4150 mg/kg bw (OECD 401, Hüls AG, 1985) and a dermal LD50 of > 5000 mg/kg bw (OECD 402, Hüls AG, 1985) . Mortalities were observed in the oral acute toxicity study at doses > 3160 mg/kg bw. Clinical signs after oral administration like ruffled fur 30 min after application, later: crouched posture, some cases of slight sedation and ataxia, staggering gait, prone position, cyanosis of the extremities, hypothermia, and narrowed or closed palpebral fissures. At 24 h additional observations, like Diarrhea and increased diuresis were made. In the two highest dose groups (i.e. 5010 and 6310 mg/kg bw respectively), difficulties with breathing, uttering sounds when touched and towards the end of the study ruffled fur in 2 animals from the high dose group were observed. Other signs disappeared approximately by day 10.
For the dermal acute toxicity study no mortalities up to a dose of 5000 mg/kg bw were observed. Clinical signs immediately after treatment were vehement defense reactions, uttering sounds, both attributed to fixation of the patch. At 1 hour the following observations were made: ruffled fur, streched posture, temporary prone position or retarded motion, staggering gait, hypothermia and slight sedation. In the application area necrosis, incrustation of application area, wounds partly with discharge, and formation of scars were observed.
Necropsy findings were Hyperemia of the smal intestinal mucosa and in one animal formation of flecks on the kidneys. The body weight was transiently inhibited.
Dermal exposure has to be avoided because of sensitizing properties.
Justification for selection of acute toxicity – oral endpoint
Only one study available
Justification for selection of acute toxicity – inhalation endpoint
According to REACH Annex VIII , Column 1, Chapter 8.5, the substance was tested via the oral and dermal route of exposure. Therefore a testing via the inhalative route of exposure is not necessary.
Justification for selection of acute toxicity – dermal endpoint
Only one study available
Justification for classification or non-classification
Based on the results of the acute oral and dermal studies and according to the criteria of EC Directive 67/548/EEC and EC Regulation 1272/2008 1,3,3 -trimethyl-N-(2 -methylpropylidene)-5 -[(2 -methylpropylidene)amino]cyclohexanemethylamine has only low acute toxicity if swallowed or dermally applied. Therefore, the test substance must not be classified.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.